Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060454 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| Hydrochloric Acid SCHEMBL20271899 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| Hydrochloric Acid SCHEMBL29463387 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL12673206 | 0.96 | SIGMAR1 (1.00) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL25066829 | 0.92 | SIGMAR1 (0.85) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL31061066 | 0.84 | SIGMAR1 (0.73) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL8000332 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL9247478 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR1A | |
| SCHEMBL9249152 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR1A | |
| SCHEMBL8021562 | 0.82 | SIGMAR1 (0.70) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | claimed |
| US-20250304793-A1 | COLORED TITANIUM DIOXIDE ASPHALT COMPOSITIONS | COOLSEAL LLC | 2025-10-02 | — | — | US | claimed |
| US-20250084279-A1 | TRANSPARENT MATTE ANTI-STAIN CORROSION-RESISTANT SURFACE COATING AND COLORED ANTI-STAIN CORROSION-RESISTANT SURFACE COATING FOR DIRECT AMBIENT TEMPERATURE MOISTURE-CURED TOPCOAT APPLICATIONS | RAYOUNG CHEMTECH INC. (TW) | 2025-03-13 | — | — | US | claimed |
| CN-118995046-A | Colored anti-fouling and corrosion-resistant surface coating, application thereof, colored anti-fouling and corrosion-resistant surface layer and colored anti-fouling and corrosion-resistant metal | 雷旸科技实业股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-115799787-B | LTCC band-pass filter with high suppression degree | 扬州江嘉科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-4326822-A1 | COLORED TITANIUM DIOXIDE ASPHALT COMPOSITIONS | CoolSeal LLC (US) | 2024-02-28 | — | — | EP | claimed |
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4149496-A1 | SARS-COV-2-SPECIFIC T CELLS | Board of Regents, The University of Texas System (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115799787-A | LTCC band-pass filter with high suppression degree | 扬州江嘉科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | claimed |
| US-20220401553-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO. KG (DE) | 2022-12-22 | — | — | US | claimed |
| WO-2022225662-A1 | COLORED TITANIUM DIOXIDE ASPHALT COMPOSITIONS | GuardTop, LLC (US) | 2022-10-27 | — | — | WO | claimed |
| WO-2022213076-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | BAYLOR COLLEGE OF MEDICINE (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | claimed |
| US-20220193204-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-23 | — | — | US | claimed |
| CN-216514469-U | Multi-guide-bar device for lace and warp knitting and warp-knitted spacer fabric cloth thereof | 福建省晋江市华宇织造有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3969036-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | Baylor College of Medicine (US) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | SIGMAR1 1688/4885CHRM2 4299/4885CHRM4 4536/4885 |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885CHRM2 3184/4885CHRM4 2292/4885 |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | IGF2BP3, RBM3, MORF4L1 | SIGMAR1 9/4885CHRM2 1493/4885CHRM4 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.